The eCTD Upgrade: Cross-Application Linking - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The eCTD Upgrade: Cross-Application Linking
How to cut time and cost by re-using already submitted documents.


Pharmaceutical Technology
Volume 34, Issue 2

Increasing drug-development costs, patent expirations, and fewer blockbuster drugs in the pipeline are forcing life-science companies to find faster, more cost-effective ways of getting new drugs approved and onto store shelves.

The worldwide shift toward the Common Technical Document (CTD) submission format promises a standardized global approach, while its electronic version, the eCTD, offers the functionality of digital-document management, manipulation, and storage. Both can streamline and speed the drug approval process.

Although industry has been anticipating these submission process changes since 2003, many drugmakers have been slow to make the transition to the eCTD. As a result, busy regulatory operations managers and staffs are being forced to face a stiff learning curve, and some eCTD technical advantages are being lost due to the lack of planning and understanding.

This article examines cross-application linking, an eCTD feature that allows sponsors to submit some required documents and data once and then refer back to those items in later eCTD applications or submissions. This means, for example, that sponsors building a New Drug Application (NDA) can link back via the extensible markup language (XML) backbone (by placing a "virtual" leaf element in the directory tree) to protocol, Chemistry, Manufactory, and Controls (CMC), or pharmacology and toxicology information already submitted and reviewed in the product's Investigational New Drug (IND) application. The link is seamless from the reviewer's viewpoint–with only the leaf title indicating that the document resides in an earlier eCTD submission. The sponsor can eliminate submission publishing and validation costs by substituting a reference link for the full document.

eCTD essentials

Because the CTD is a submission format, the content requirements for an IND, NDA, Marketing Authorization Application (MAA), or any other regulatory submission do not change. The format does, however, organize the required documentation into smaller chunks of information called "granules" that are easily assembled and managed over the application's lifetime. These granules are placed into a rigid, well-defined folder structure that allows sponsors and regulators to take a more consistent and harmonized approach to submission building and review.

Whereas the CTD is a paper submission that is hand-delivered, the eCTD is an XML-based version that is sent through electronic media or secure regulator gateways. Among the advantages of electronic transmission, management and storage, the eCTD allows sponsors to link to documents within and across previously filed submissions and applications. This feature can save time and the cost of publishing and maintaining a submission or application, but only if properly set up and managed from the start of the product IND eCTD application.

The primary technical components of the eCTD, which reside in the XML "backbone", are:

  • Document type definitions (the submission format "rulebook")
  • Style sheets (formats and styles used to view the XML backbone)
  • Submission metadata (information 'tags' associated with applications and documents and used within the XML backbone)
  • The XML backbone, which replaces submission-level and module-level tables of contents.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here